Motiva

Establishment Labs Announces Amended Credit Facility with Oaktree

Retrieved on: 
Thursday, February 22, 2024
Medical Devices, Health, Consumer, Surgery, Women, Health Technology, ESTA, FDA, Oaktree Capital Management, Form, Interest, Motiva, Security (finance), Tranche

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
  • The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged.
  • “This amended facility provides access to additional capital, should we need it, to ensure our successful launch of Motiva Implants in the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • We look forward to continuing our long-term relationship with Establishment Labs and are excited for what lies ahead.”
    A Form 8-K outlining the full terms of the credit facility will be filed with the Securities and Exchange Commission.

Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

Retrieved on: 
Tuesday, January 2, 2024
Surgery, Medical Devices, Women, Health Technology, Biotechnology, Health, Consumer, General Health, Oncology, Rabbit, MRI, Motiva, ESTA, FDA, Magnet, Mouse, MD, Human, Inflammation, University, Establishment, MD Anderson Cancer Center, Radiation, RFID, Patient, Plastic surgery, Medical imaging

The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery.

Key Points: 
  • The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery.
  • "This Flora device is a new resource in our toolkit for breast cancer reconstruction,” Dr. Clemens noted.
  • The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA.
  • By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment.

Global Partners LP Completes Acquisition of 25 Liquid Energy Terminals from Motiva Enterprises LLC

Retrieved on: 
Thursday, December 21, 2023
Retail, Energy, Convenience Store, Oil, Gas, Gasoline, Partner, Motiva, Acquisition, Slifka, Global Partners, Exploration, Growth, Colonial, Motiva Enterprises, Ferdinand Magellan, Commercial property

Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today announced the completion of its previously announced acquisition of 25 liquid energy terminals from Motiva Enterprises LLC (“Motiva”).

Key Points: 
  • Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today announced the completion of its previously announced acquisition of 25 liquid energy terminals from Motiva Enterprises LLC (“Motiva”).
  • The transaction is underpinned by a 25-year take-or-pay throughput agreement with Motiva, the anchor tenant at the terminals, that includes minimum annual revenue commitments.
  • “This acquisition nearly doubles our operating footprint, giving Global a significant position from Maine to Florida and into the Gulf Coast,” said Eric Slifka, the Partnership’s President and Chief Executive Officer.
  • The new assets expand access to a critical network of marine loading facilities as well as the Colonial, Plantation, Enterprise, Explorer and Magellan refined product pipelines.

Motiva Announces Retirement of Bill Spurgeon, Executive Vice President of Marketing, Sales & Logistics

Retrieved on: 
Friday, December 1, 2023
Retirement, Shell, Motiva Enterprises, Commercial, Management, Motiva, Marketing

As a result of Spurgeon's retirement, Motiva is implementing organizational changes to re-align various operational and commercial activities. Motiva Executive Vice President of Optimization & Strategy Travis Capps has been named Motiva's Executive Vice President of Commercial -- a new organization encompassing all the commercial activities of Motiva.

Key Points: 
  • HOUSTON, Dec. 1, 2023 /PRNewswire/ -- Motiva Enterprises LLC today announced the retirement of Bill Spurgeon as Executive Vice President of Marketing, Sales & Logistics, effective December 1, 2023.
  • He joined Motiva in 2014 as Vice President of Fuel Sales & Marketing following more than two decades in various domestic and international leadership roles at Shell.
  • "Bill Spurgeon is an exceptional leader and innovative champion for the fuels industry," said Motiva President and CEO Jeff Rinker.
  • Motiva Executive Vice President of Optimization & Strategy Travis Capps has been named Motiva's Executive Vice President of Commercial -- a new organization encompassing all the commercial activities of Motiva.

Establishment Labs Announces National Medical Products Administration Approval for Motiva Implants in China

Retrieved on: 
Thursday, November 9, 2023
Women, Biotechnology, Surgery, Health, Medical Devices, Health Technology, Consumer, Other Health, Science, NMPA, ESTA, National Medical Products Administration, Perception, Diversified Specialty Institute Holdings, Inc., Medical device, Cryptocurrency, Motiva

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has received National Medical Products Administration (NMPA) approval in China for Motiva® Implants.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has received National Medical Products Administration (NMPA) approval in China for Motiva® Implants.
  • “Our approval in China marks Establishment Labs’ entry into the second largest global and most dynamic market for breast aesthetics in the world,” said Juan José Chacón-Quirós, Chief Executive Officer.
  • “This is the first breast implant technology approved in China in more than a decade.
  • “We transformed the breast aesthetics market in South Korea with Motiva, and we are excited to replicate that success in China,” added John Lim, Founder and CEO of Motiva China Ltd., Establishment Labs exclusive distribution partner in the market.

Global Partners LP to Acquire 25 Liquid Energy Terminals from Motiva Enterprises LLC

Retrieved on: 
Thursday, November 9, 2023
Energy, Other Energy, Oil, Gas, Atlantic Coast, Partner, Ferdinand Magellan, NYSE, Global Partners, Acquisition, Multimedia, Growth, Marketing, Partnership, Simon Borrows, Motiva, Motiva Enterprises, BofA Securities, Commercial property, Exploration

Global Partners LP (“Global”) (NYSE:GLP), an integrated storage, distribution and retail liquid energy company, has entered into an asset purchase agreement with Motiva Enterprises LLC (“Motiva”) to acquire 25 liquid energy terminals along the Atlantic Coast, in the Southeast and in Texas.

Key Points: 
  • Global Partners LP (“Global”) (NYSE:GLP), an integrated storage, distribution and retail liquid energy company, has entered into an asset purchase agreement with Motiva Enterprises LLC (“Motiva”) to acquire 25 liquid energy terminals along the Atlantic Coast, in the Southeast and in Texas.
  • Global has agreed to purchase the terminals, with a shell capacity of 8.4 million barrels, for $305.8 million in cash.
  • View the full release here: https://www.businesswire.com/news/home/20231108711745/en/
    On Thursday, November 9, 2023, Global Partners LP (NYSE:GLP) announced the signing of an asset purchase agreement with Motiva Enterprises LLC to acquire 25 liquid energy terminals along the Atlantic Coast, in the Southeast and in Texas for $305.8 million in cash.
  • (Graphic: Global Partners LP)
    Global currently owns or leases 24 liquid energy terminals in states throughout the Northeast and in North Dakota and Oregon.

Global Partners Reports Third-Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Professional Services, Insurance, Finance, Atlantic Coast, DCF, Partner, DC, EV, NYSE, Tax, Rain, Gasoline, EBITDA, News, GAAP, Acquisition, Generally Accepted Accounting Principles (United States), Growth, Motiva, Depreciation, Oil, Motiva Enterprises, Global Partners, Propane, Video game, Beauty salon, Natural gas, Q3

Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2023.
  • Global has agreed to purchase the terminals, which have a shell capacity of 8.4 million barrels, for $305.8 million in cash.
  • Distributable cash flow (DCF) was $42.2 million in the third quarter of 2023 compared with $128.0 million in 2022.
  • The distribution will be paid on November 14, 2023 to unitholders of record as of the close of business on November 8, 2023.

Establishment Labs Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Surgery, Medical Devices, Women, Consumer, Health, FDA, Trial of the century, ESTA, Rupture, Bleeding, Growth, U.S. FDA, Investment, Mia, Hilltop Holdings Inc., Video game, Cryptocurrency, Pharmaceutical industry, Motiva

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2023.
  • Third quarter loss from operations was $21.0 million compared to a loss of $10.5 million in the year-ago period.
  • “Our results in the third quarter and updated guidance reflect lower demand for breast procedures globally,” said Juan José Chacón-Quirós, Chief Executive Officer.
  • Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results.

Establishment Labs Announces FDA Clearance of Motiva Flora SmoothSilk Tissue Expander

Retrieved on: 
Monday, October 16, 2023
Health, Medical Devices, Other Health, Artifact, Partnership, RFID, Earnings before interest, taxes, depreciation and amortization, Food, Google Images, Metal, Breast cancer, Inflammation, Breast, Radiology, Breast pain, Michelle Brunner, Heart, VMAT, Radiation, Motiva, University, FDA, Applied science, Rabbit, CT, Magnet, Environment, Luigi Cozzi, Safety, History, Medicine, Mouse, MRI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Establishment, Human, Woman, Diversified Specialty Institute Holdings, Inc., Patient, Surgeon, ESTA, Pharmaceutical industry, Medical imaging, Omid Veiseh

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.
  • The Flora® SmoothSilk® Tissue Expander offers several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology.
  • By being magnet-free, Flora avoids the interference that magnets can cause during MRI and may improve the precision of radiation oncology treatment.
  • “This is an incredibly important day in the history of Establishment Labs, as the first of our implantable technologies has been approved by the FDA,” said Juan José Chacón-Quirós, Founder and Chief Executive Officer of Establishment Labs.

Establishment Labs Announces Two-Year Mia Femtech Clinical Results and the Launch of Zen at 8th World Symposium on Ergonomic Implants

Retrieved on: 
Friday, October 13, 2023
Women, Biotechnology, Surgery, General Health, Health, Health Technology, Consumer, Clinical Trials, Diamond, Joy, Mia, RFID, WSEI, Bleeding, Zen, Seroma, ESTA, Safety, Hematoma, Temperature, IRB, Surgeon, Kaplan–Meier estimator, Diversified Specialty Institute Holdings, Inc., Medical device, Motiva

The Mia Feasibility Clinical Study is an IRB-approved prospective study that enrolled 100 subjects between December 2020 and April 2021.

Key Points: 
  • The Mia Feasibility Clinical Study is an IRB-approved prospective study that enrolled 100 subjects between December 2020 and April 2021.
  • A sub-study of 33 subjects underwent an MRI at 18 months with no ruptures in the cohort.
  • *
    In addition to announcing the Mia study data, Establishment Labs is also launching Zen™, which is part of its next generation Zensor™ RFID platform.
  • Motiva Ergonomix2 Diamond implants used in the Mia Femtech system feature Zen, and it will initially be available in select geographies with Motiva Ergonomix2 Round implants in the Joy program.